- Juvenile NCL (JNCL)
- Infantile NCL (INCL)
- Late infant NCL (LINCL)
- Adult NCL
- Others
Batten Disease Treatment Market size was valued at expected to grow at a CAGR of 5.4% from 2023 to 2029. The global market provides a detailed overview and which can be segmented by type of disease, treatment, distribution channel, and region. By type of disease, the market has been segmented into juvenile NCL (JNCL), infantile NCL (INCL), late infant NCL (LINCL), adult NCL, and others. By treatment, the adult NCL segment held the largest revenue share of the batten disease treatment market in historic years and is expected to have a significant growth rate over the forecasted period due to the rising adult population suffering from batten disease. By treatment, the has been segmented into gene therapy, drug therapy, enzyme therapy, and others. By treatment, the drug therapy segment held the maximum revenue share of the batten disease treatment market and is anticipated to have a significant growth rate during the forecasted period due to continuous advancement in drug therapy by increasing investment in the healthcare system. By distribution channel, the batten disease treatment market has been segmented into hospital pharmacies, retail pharmacies, and others. By treatment type, the hospital segment held the largest revenue share of the batten disease treatment market in past years and is expected to have the fastest growth rate over the forecasted period due to a high patient population proportion worldwide.
Batten Disease Treatment Market Key Development:
- In June 2021 Neurogene Inc., a company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to its adeno-associated virus (AAV) encoding a codon-optimized human CLN5 transgene (hCLN5) for patients diagnosed with CLN5, a subtype of Batten disease.
Batten Disease Treatment Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
5.4%
Largest Market
North America
Fastest Growing Market
North America
Batten Disease Treatment Market Dynamics
Increase in the incidence of neurological disorders, and also a rise in the investment of biotechnology and pharmaceutical industries in research and development is further expected the growth of the batten disease treatment market. Moreover, the increasing demand for better treatment methods is further estimated to boosting the growth of the batten disease treatment market. Apart from this, the presence of fewer drugs accepted for batten disease is further projected to obstruct the growth of the batten disease treatment market in the timeline period.
North-America Got Significant Share
Batten Disease Treatment Market Regional Analysis
North America is expected to have a significant amount of growth in the batten disease treatment market due to an increase in the prevalence rates of batten diseases in many advancing countries of this region. Furthermore, the rise in healthcare facilities is also anticipated to propel the growth of the batten disease treatment market in the region in the coming few years.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Batten Disease Treatment Market Segmentation
By Type of Disease
By Treatment
- Gene Therapy
- Drug Therapy
- Enzyme Therapy
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
Frequently Asked Questions
The major factors driving the market growth are the rising incidence of neurological disorders, and also a rise in the investment of biotechnology and pharmaceutical industries in research and development, and the launch & adoption of several drugs for the treatment of the batten disease treatment market.
The global batten disease treatment market is expected to grow at a CAGR of 5.4% during the forecast period 2022 to 2028.
Huge investment in healthcare systems and acquisition are the two key strategies opted for by the leading companies in the market.
The Healthcare system is getting huge support from the government around the globe. Cohesive policies and government support improved the healthcare system of the world. For instance, the US spends over $10,000 per individual, which is the highest healthcare spending across the world. Other developed economies such as the UK, Germany, and Canada, among others, inject a significant amount of money into the healthcare system. Even emerging economies including China, Korea, India, Korea, and Thailand are also increasing their healthcare spending.
| 1.Executive Summary |
| 2.Global Batten Disease Treatment Market Introduction |
| 2.1.Global Batten Disease Treatment Market - Taxonomy |
| 2.2.Global Batten Disease Treatment Market - Definitions |
| 2.2.1.Type of Disease |
| 2.2.2.Treatment |
| 2.2.3.Distribution Channel |
| 2.2.4.Region |
| 3.Global Batten Disease Treatment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Batten Disease Treatment Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Batten Disease Treatment Market By Type of Disease, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 5.1. Juvenile NCL (JNCL) |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Infantile NCL (INCL) |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Late infant NCL (LINCL) |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Adult NCL |
| 5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Others |
| 5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6.Global Batten Disease Treatment Market By Treatment, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 6.1. Gene Therapy |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Drug Therapy |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Enzyme Therapy |
| 6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Others |
| 6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 7.Global Batten Disease Treatment Market By Distribution Channel, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 7.1. Hospital Pharmacies |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Retail Pharmacies |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Others |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8.Global Batten Disease Treatment Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Batten Disease Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 9.1. Type of Disease Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Juvenile NCL (JNCL) |
| 9.1.2.Infantile NCL (INCL) |
| 9.1.3.Late infant NCL (LINCL) |
| 9.1.4.Adult NCL |
| 9.1.5.Others |
| 9.2. Treatment Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Gene Therapy |
| 9.2.2.Drug Therapy |
| 9.2.3.Enzyme Therapy |
| 9.2.4.Others |
| 9.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospital Pharmacies |
| 9.3.2.Retail Pharmacies |
| 9.3.3.Others |
| 9.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Batten Disease Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 10.1. Type of Disease Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Juvenile NCL (JNCL) |
| 10.1.2.Infantile NCL (INCL) |
| 10.1.3.Late infant NCL (LINCL) |
| 10.1.4.Adult NCL |
| 10.1.5.Others |
| 10.2. Treatment Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Gene Therapy |
| 10.2.2.Drug Therapy |
| 10.2.3.Enzyme Therapy |
| 10.2.4.Others |
| 10.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospital Pharmacies |
| 10.3.2.Retail Pharmacies |
| 10.3.3.Others |
| 10.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 10.4.6.Rest of EU |
| 10.4.7. |
| 11.Asia Pacific (APAC) Batten Disease Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 11.1. Type of Disease Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Juvenile NCL (JNCL) |
| 11.1.2.Infantile NCL (INCL) |
| 11.1.3.Late infant NCL (LINCL) |
| 11.1.4.Adult NCL |
| 11.1.5.Others |
| 11.2. Treatment Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Gene Therapy |
| 11.2.2.Drug Therapy |
| 11.2.3.Enzyme Therapy |
| 11.2.4.Others |
| 11.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospital Pharmacies |
| 11.3.2.Retail Pharmacies |
| 11.3.3.Others |
| 11.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Batten Disease Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 12.1. Type of Disease Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Juvenile NCL (JNCL) |
| 12.1.2.Infantile NCL (INCL) |
| 12.1.3.Late infant NCL (LINCL) |
| 12.1.4.Adult NCL |
| 12.1.5.Others |
| 12.2. Treatment Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Gene Therapy |
| 12.2.2.Drug Therapy |
| 12.2.3.Enzyme Therapy |
| 12.2.4.Others |
| 12.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospital Pharmacies |
| 12.3.2.Retail Pharmacies |
| 12.3.3.Others |
| 12.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Batten Disease Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 13.1. Type of Disease Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Juvenile NCL (JNCL) |
| 13.1.2.Infantile NCL (INCL) |
| 13.1.3.Late infant NCL (LINCL) |
| 13.1.4.Adult NCL |
| 13.1.5.Others |
| 13.2. Treatment Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Gene Therapy |
| 13.2.2.Drug Therapy |
| 13.2.3.Enzyme Therapy |
| 13.2.4.Others |
| 13.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospital Pharmacies |
| 13.3.2.Retail Pharmacies |
| 13.3.3.Others |
| 13.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Abeona Therapeutics Inc. (U.S.) |
| 14.2.2.BioMarin Pharmaceutical Inc. (U.S.) |
| 14.2.3.CereSpir Inc. (U.S.) |
| 14.2.4.Evotec AG (Germany) |
| 14.2.5.Ionis Pharmaceuticals Inc. (U.S.) |
| 14.2.6.Mitochon Pharmaceuticals Inc. (U.S.) |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
- Abeona Therapeutics Inc. (U.S.)
- BioMarin Pharmaceutical Inc. (U.S.)
- CereSpir Inc. (U.S.)
- Evotec AG (Germany)
- Ionis Pharmaceuticals Inc. (U.S.)
- Mitochon Pharmaceuticals Inc. (U.S.)
- Spark Therapeutics Inc. (U.S.)